title: [The combination of chronic myeloid leukemia and multiple myeloma in one patient].
abstract: The article describes the clinical observation of a patient with simultaneous course of lymphoid and myeloid neoplasms. The patient developed two diseases--chronic myeloid leukemia (CML) and multiple myeloma (MM), which were confirmed by corroborated hemogram, myelogram, immunophenotyping of bone marrow cells, biopsy, immunohistochemical, cytogenetic, biochemical and radiological studies. Target therapy of CML with tyrosine kinase inhibitors (imatinib at the standard dose of 400 mg per day) has provided a complete cytogenetic remission at 6 months and major molecular response at 18 months of treatment. Administration of 2 courses of programmed treatment "BD" > (bortezomib + dexamethasone) resulted in a very good partial response, which was maintained through a year and a half. However, against the background of programmed treatment there were developed complications as polyneuropathy of grade 2, which was treated with thioctacide, milgamy, and anemia of grade 2, successfully treated with epoetin beta. Subsequently, the patient was administered continuously with imatinib 400 mg that kept the major molecular response. Relapsed MM was revealed in 20 months and confirmed by a full clinical and hematological examination. The absence of organ dysfunction allowed choosing a supervisory tactics for the patient.
authors.forename: N A
authors.initials: NA
authors.lastname: Romanenko
authors.forename: S S
authors.initials: SS
authors.lastname: Bessmel'tsev
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Udal'eva
authors.forename: M N
authors.initials: MN
authors.lastname: Zenina
authors.forename: I S
authors.initials: IS
authors.lastname: Martynkevich
authors.forename: V I
authors.initials: VI
authors.lastname: Rugal'
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D060828:Induction Chemotherapy; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011115:Polyneuropathies / Q000139:chemically induced; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D057832:Watchful Waiting
chemical_list: D001549:Benzamides; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D010879:Piperazines; D011719:Pyrazines; D011743:Pyrimidines; D000069286:Bortezomib; D003907:Dexamethasone; D000068877:Imatinib Mesylate